LENZ on Nasdaq

LENZ Therapeutics, Inc.

American biological products company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Cullinan Oncology, Alector (United States) or Mesoblast, or pick any stock.

TickerLENZ on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE²
Business address201 Lomas Santa Fe Drive, Suite 300, Solana Beach, Ca 92075²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-477.5%Operating margin³

-430.3%Net margin³

-28.9%Return on equity³

-$70.0MFree cash flow³

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License brought in 92% of the revenue LENZ Therapeutics, Inc. broke down this way in fiscal 2025.

License$17.5M³92%
Product$1.6M³8%

Products and services by year

Products and services	2024	2025
License	$0	$17.5M
Product	$0	$1.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and developmentSelling, general and admin

Cost of revenue0¢$418.0K
Research and development17¢$18.7M
Selling, general and admin82¢$91.1M
Income tax0¢$502.0K

Out of $19.1M in revenue.³ The company lost money this year.

Financial statements

Revenue³$19.1M in 2025

Operating income⁴⁵⁶⁷³-$91.1M in 2025+575% since 2020

Net income⁴⁵⁶⁷³-$82.1M in 2025+20% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Total revenue	$19.1M	$0
Cost of sales	$418.0K	$0
Selling, general and administrative	$91.1M	$28.8M
Research and development	$18.7M	$29.8M
Total operating expenses	$110.2M	$58.6M
Loss from operations	-$91.1M	-$58.6M
Other (expense) income	-$243.0K	$289.0K
Interest income	$9.8M	$8.6M
Total other income, net	$9.5M	$8.8M
Net loss before income taxes	-$81.6M	-$49.8M
Income tax expense	$502.0K	$1.0K
Net loss	-$82.1M	-$49.8M
Unrealized gain on marketable securities	$46.0K	$190.0K
Comprehensive loss	-$82.1M	-$49.6M
Net loss per share - basic (in dollars per share)	-$2.85	-$2.34
Net loss per share - diluted (in dollars per share)	-$2.85	-$2.34
Weighted-average common shares outstanding, basic (in shares)	28.8M shares	21.3M shares
Weighted-average common shares outstanding, diluted (in shares)	28.8M shares	21.3M shares

Total assets⁴⁵⁶⁷³$305.9M in 2025+1256% since 2020

Total liabilities⁴⁵⁶⁷³$21.5M in 2025−33% since 2020

Shareholders’ equity⁴⁵⁶⁷³$284.3M in 2025

Cash⁴⁵⁶⁷³$25.2M in 2025+27% since 2020

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$25.2M	$20.2M
Marketable securities	$267.2M	$188.9M
Accounts receivable, net	$329.0K	$0
Inventory	$2.9M	$0
Prepaid expenses and other current assets	$5.8M	$2.8M
Restricted cash	$0	$114.0K
Total current assets	$301.4M	$211.9M
Property and equipment, net	$1.2M	$651.0K
Operating lease right-of-use asset	$734.0K	$1.3M
Other assets	$2.5M	$1.4M
Total assets	$305.9M	$215.3M
Accounts payable	$4.2M	$4.3M
Accrued liabilities	$17.0M	$6.1M
Total current liabilities	$21.2M	$10.4M
Operating lease liability, net	$350.0K	$814.0K
Total liabilities	$21.5M	$11.2M
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issues and outstanding at December 31, 2025 and 2024	$0	$0
Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2025 and 2024; 31,344,782 and 27,531,490 shares issued at December 31, 2025 and 2024, respectively; and 31,344,782 and 27,518,439 shares outstanding at December 31, 2025 and 2024, respectively	$1.0K	$1.0K
Additional paid-in capital	$511.2M	$348.9M
Accumulated deficit	-$227.1M	-$145.0M
Accumulated other comprehensive income	$242.0K	$196.0K
Total stockholders equity	$284.3M	$204.1M	-$92.7M
Total liabilities and stockholders equity	$305.9M	$215.3M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, issued (in shares)	0 shares	0 shares
Preferred stock, outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	300.0M shares	300.0M shares
Common stock, issued (in shares)	31.3M shares	27.5M shares
Common stock, outstanding (in shares)	31.3M shares	27.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$25.2M	$20.2M
Marketable securities	$267.2M	$188.9M
Accounts receivable, net	$329.0K	$0
Inventory	$2.9M	$0
Prepaid expenses and other current assets	$5.8M	$2.8M
Restricted cash	$0	$114.0K
Total current assets	$301.4M	$211.9M
Property and equipment, net	$1.2M	$651.0K
Operating lease right-of-use asset	$734.0K	$1.3M
Other assets	$2.5M	$1.4M
Total assets	$305.9M	$215.3M
Accounts payable	$4.2M	$4.3M
Accrued liabilities	$17.0M	$6.1M
Total current liabilities	$21.2M	$10.4M
Operating lease liability, net	$350.0K	$814.0K
Total liabilities	$21.5M	$11.2M
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issues and outstanding at December 31, 2025 and 2024	$0	$0
Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2025 and 2024; 31,344,782 and 27,531,490 shares issued at December 31, 2025 and 2024, respectively; and 31,344,782 and 27,518,439 shares outstanding at December 31, 2025 and 2024, respectively	$1.0K	$1.0K
Additional paid-in capital	$511.2M	$348.9M
Accumulated deficit	-$227.1M	-$145.0M
Accumulated other comprehensive income	$242.0K	$196.0K
Total stockholders equity	$284.3M	$204.1M	-$92.7M
Total liabilities and stockholders equity	$305.9M	$215.3M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, issued (in shares)	0 shares	0 shares
Preferred stock, outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	300.0M shares	300.0M shares
Common stock, issued (in shares)	31.3M shares	27.5M shares
Common stock, outstanding (in shares)	31.3M shares	27.5M shares

Cash from operations⁴⁵⁶⁷³-$69.2M in 2025+693% since 2020

Capital spending⁴⁵⁶⁷³$827.0K in 2025−46% since 2020

Free cash flow⁴⁵⁶⁷³-$70.0M in 2025+582% since 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31
Net loss	-$82.1M	-$49.8M
Depreciation and amortization	$287.0K	$58.0K
Loss on disposal of property and equipment	$0	$16.0K
Loss on impairment of operating right-of-use assets and related property and equipment	$82.0K	$0
Accretion of discounts and amortization of premiums on marketable securities, net	-$3.4M	-$4.0M
Loss (gain) on long-term investments, net	$197.0K	-$1.3M
Change in fair value of preferred stock warrants	$0	$1.0M
Share-based compensation expense	$12.5M	$6.4M
Accounts receivable, net	-$329.0K	$0
Inventory	-$4.3M	$0
Prepaid expenses and other current assets	-$3.0M	$25.0K
Accounts payable	-$90.0K	-$4.3M
Accrued liabilities	$11.0M	-$7.5M
Other assets	-$1.0K	-$41.0K
Net cash used in operating activities	-$69.2M	-$59.4M
Purchases of marketable securities	-$280.8M	-$241.9M
Proceeds from maturities of marketable securities	$206.0M	$87.9M
Purchases of property and equipment	-$827.0K	-$468.0K
Net cash used in investing activities	-$75.7M	-$154.5M
Proceeds from exercises of stock options	$1.1M	$4.0M
Proceeds from issuance of common stock under employee stock purchase plan	$873.0K	$0
Cash, cash equivalents, and restricted cash acquired in connection with the Merger	$0	$117.8M
Merger transaction costs	$0	-$2.4M
Net cash provided by financing activities	$149.7M	$199.0M
Net increase (decrease) in cash, cash equivalents, and restricted cash	$4.9M	-$14.9M
Reclassification of warrant liability to equity	$0	$1.9M
Prepaid expenses and other current assets assumed in the Merger	$0	$1.3M
Accounts payable and accrued liabilities assumed in the Merger	$0	$3.0M
Right-of-use assets assumed in the Merger in exchange for operating lease liabilities	$0	$74.0K
Right-of-use assets obtained in exchange for operating lease liabilities	$0	$1.1M
Property and equipment included in accounts payable and accrued expenses	$0	$203.0K

Compare LENZ Therapeutics, Inc. with another company

Leadership

Who has led LENZ Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Katherine Stultz V.2021

2025

Chief executive officerEvert B. Schimmelpennink Mar 25, 2024 to now¹⁰
Chief executive officerJoshua Lehrer-Graiwer Jun 24, 2021 to Feb 23, 2023¹¹
PresidentEvert B. Schimmelpennink Mar 25, 2024 to now¹⁰
PresidentJoshua Lehrer-Graiwer Jun 24, 2021 to Feb 23, 2023¹¹
Chief financial officerDaniel R. Chevallard Mar 25, 2024 to now¹²
Chief financial officerAlethia Young Apr 5, 2022 to Feb 23, 2023¹³
Chief operating officerKatherine Stultz V. Jun 24, 2021 to Jul 1, 2021¹⁴

Board members and other officers (22)

Chief Medical OfficerMarc Odrich Mar 25, 2024 to now¹⁵
Chief Commercial OfficerShawn Olsson Mar 25, 2024 to now¹⁶
CHIEF BUSINESS OFFICERPhil Gutry Jun 24, 2021 to Apr 13, 2022¹⁷
Board memberEvert B. Schimmelpennink Mar 25, 2024 to now¹⁰
Board memberFrederic Guerard Mar 25, 2024 to now¹⁸
Board memberJames W. McCollum Mar 25, 2024 to now¹⁹
Board memberJeffrey P. George Mar 25, 2024 to now²⁰
Board memberPeter Kolchinsky Mar 25, 2024 to now²¹
Board memberRajeev M. Shah Mar 25, 2024 to now²¹
Board memberShelley B. Thunen Mar 25, 2024 to now²²
Board memberZachary Scheiner Mar 25, 2024 to now²³
Board memberKimberlee C. Drapkin Aug 1, 2023 to now²⁴
Board memberAbraham Bassan Jun 24, 2021 to Jul 21, 2023²⁵
Board memberDavis Jerel Jun 24, 2021 to Jul 21, 2023²⁶
Board memberJoanne L. Viney Jun 24, 2021 to Jul 21, 2023²⁷
Board memberJoseph Jimenez Jun 24, 2021 to Jul 21, 2023²⁸
Board memberJoshua Lehrer-Graiwer Jun 24, 2021 to Feb 23, 2023¹¹
Board memberKristen Hege Jun 24, 2021 to Jul 21, 2023²⁹
Board memberMatthew Porteus Jun 24, 2021 to Jul 21, 2023³⁰
Board memberPerry A. Karsen Jun 24, 2021 to Jul 21, 2023³¹
Board memberRizzuto Carlo Jun 24, 2021 to Jul 21, 2023³²
Board memberSmital Shah Jun 24, 2021 to Jul 21, 2023³³

Former names

Graphite Bio, Inc.Mar 19, 2021 to Mar 19, 2024²

Timeline

Mar 25, 2024New chief executive Evert B. Schimmelpennink becomes CEO¹⁰
Jun 24, 2021New chief executive Joshua Lehrer-Graiwer becomes CEO¹¹

Filings

295 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 57 major events, 101 insider forms, 40 large holders, 76 other. The latest 20:

Sep 8, 2026SCHEDULE 13G/A EDGAR
Aug 11, 202610-Q EDGAR
Aug 11, 20268-K EDGAR
Jul 2, 20268-K EDGAR
Jun 26, 2026SCHEDULE 13G EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 12, 20268-K EDGAR
May 11, 202610-Q EDGAR
May 11, 20268-K EDGAR
Apr 28, 2026ARS EDGAR
Apr 28, 2026DEFA14A EDGAR
Apr 28, 2026DEF 14A EDGAR
Apr 27, 2026SCHEDULE 13G EDGAR
Apr 8, 2026SCHEDULE 13G EDGAR

The 295 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 40 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Ra Capital Management, L.P.	4,178,823	$23.7M	0.2%	No change
Alpha Wave Global, LP	3,612,211	$20.5M	0.3%	No change
Fmr LLC	3,558,905	$20.2M	0.0%	−38,879
Versant Venture Management, LLC	2,656,888	$15.1M	9.3%	No change
BlackRock, Inc.	2,292,121	$13.0M	0.0%	+315,298
Squarepoint Ops LLC	1,747,096	$9.9M	0.0%	+240,597
Aberdeen Group plc	1,547,883	$8.8M	0.0%	+391,722
Millennium Management LLC	1,508,478	$8.6M	0.0%	+639,221
Vanguard Capital Management LLC	1,097,755	$6.2M	0.0%	+56,567
72 Investment Holdings, LLC	1,017,751	$5.8M	11.6%	No change
Blue Owl Capital Holdings LP	756,722	$4.3M	0.7%	+250,000
Geode Capital Management, LLC	564,662	$3.2M	0.0%	+40,088
Trexquant Investment LP	497,526	$2.8M	0.0%	+283,118
Marshall Wace, Llp	493,099	$2.8M	0.0%	+332,835
Qube Research & Technologies Ltd	482,195	$2.7M	0.0%	New
Morgan Stanley	472,995	$2.7M	0.0%	−175,853
Primecap Management Co/ca/	472,200	$2.7M	0.0%	No change
Tang Capital Management LLC	451,114	$2.6M	0.1%	No change
Alyeska Investment Group, L.P.	438,882	$2.5M	0.0%	−24,613
State Street Corp	406,674	$2.3M	0.0%	+4,449
Citadel Advisors LLC	363,229	$2.1M	0.0%	New
Two Sigma Investments, LP	285,584	$1.6M	0.0%	−215,413
Rock Springs Capital Management LP	257,460	$1.5M	0.1%	No change
Bank Of America Corp /de/	255,410	$1.5M	0.0%	−292,124
Discovery Capital Management, LLC / Ct	241,300	$1.4M	0.1%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARLENZ Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARLENZ Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARLENZ Therapeutics, Inc. 10-K for fiscal 2025
4
SEC EDGARLENZ Therapeutics, Inc. 10-K for fiscal 2020
5
SEC EDGARLENZ Therapeutics, Inc. 10-K for fiscal 2021
6
SEC EDGARLENZ Therapeutics, Inc. 10-K for fiscal 2022
7
SEC EDGARLENZ Therapeutics, Inc. 10-K for fiscal 2023
8
SEC EDGARLENZ Therapeutics, Inc. 10-Q for fiscal 2026
9
SEC EDGARLENZ Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGAREvert B. Schimmelpennink, Chief executive officer
11
SEC EDGARJoshua Lehrer-Graiwer, Chief executive officer
12
SEC EDGARDaniel R. Chevallard, Chief financial officer
13
SEC EDGARAlethia Young, Chief financial officer
14
SEC EDGARKatherine Stultz V., Chief operating officer
15
SEC EDGARMarc Odrich, Chief Medical Officer
16
SEC EDGARShawn Olsson, Chief Commercial Officer
17
SEC EDGARPhil Gutry, CHIEF BUSINESS OFFICER
18
SEC EDGARFrederic Guerard, Board member
19
SEC EDGARJames W. McCollum, Board member
20
SEC EDGARJeffrey P. George, Board member
21
SEC EDGARPeter Kolchinsky, Board member
22
SEC EDGARShelley B. Thunen, Board member
23
SEC EDGARZachary Scheiner, Board member
24
SEC EDGARKimberlee C. Drapkin, Board member
25
SEC EDGARAbraham Bassan, Board member
26
SEC EDGARDavis Jerel, Board member
27
SEC EDGARJoanne L. Viney, Board member
28
SEC EDGARJoseph Jimenez, Board member
29
SEC EDGARKristen Hege, Board member
30
SEC EDGARMatthew Porteus, Board member
31
SEC EDGARPerry A. Karsen, Board member
32
SEC EDGARRizzuto Carlo, Board member
33
SEC EDGARSmital Shah, Board member